Results from the phase 3 Myeloma XI trial bolster earlier evidence that maintenance therapy with lenalidomide is associated with improved PFS for some patients with multiple myeloma.
from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2RrHtvo
from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2RrHtvo